Spanish researchers identify vulnerable window to eradicate early brain metastases with existing drugs
Scientists at the CNIO uncovered a brief phase in early brain metastases that can be cleared using three drugs, two of which are already approved for other conditions.
A study published in Cancer Cell by the Grupo de Metástasis Cerebrales at the Centro Nacional de Investigaciones Oncológicas describes a short, vulnerable stage in the development of brain metastases. During this "proliferative pause," metastatic cells temporarily suspend aggressive growth, creating a therapeutic opening. Manuel Valiente's group showed in mouse experiments and human tissue specimens that a combination of three drugs—two already authorized for other indications—can eradicate micrometastases before they become clinically apparent.
Researchers suggest this could be the first strategy to prevent brain metastases, but experts warn that reliable biomarkers and safety validation are required. Pilar Sánchez Gómez emphasized the need to identify patients with micrometastases and to study how this pause interacts with radiotherapy. Future investigations will assess whether a similar vulnerable window exists in other cancer types.
Why it matters
Early elimination of brain micrometastases could dramatically lower cancer-related deaths from metastatic spread.
In this story
